Idiosyncratic drug-induced liver injury and the role of inflammatory stress with an emphasis on an animal model of trovafloxacin hepatotoxicity - Wikidata - wikimedia - TriplyDB

Idiosyncratic drug-induced liver injury and the role of inflammatory stress with an emphasis on an animal model of trovafloxacin hepatotoxicity

Idiosyncratic drug-induced liver injury and the role of inflammatory stress with an emphasis on an animal model of trovafloxacin hepatotoxicity

http://www.wikidata.org/entity/Q34200596

about

Pathogenesis of idiosyncratic drug-induced liver injury and clinical perspectives.Concurrent Inflammation Augments Antimalarial Drugs-Induced Liver Injury in Rats Bioprinted 3D Primary Liver Tissues Allow Assessment of Organ-Level Response to Clinical Drug Induced Toxicity In Vitro Relationships Between Pharmacovigilance, Molecular, Structural, and Pathway Data: Revealing Mechanisms for Immune-Mediated Drug-Induced Liver Injury.Trovafloxacin enhances lipopolysaccharide-stimulated production of tumor necrosis factor-α by macrophages: role of the DNA damage response.Drug-Induced Liver Injury: Cascade of Events Leading to Cell Death, Apoptosis or Necrosis Multi-cell type human liver microtissues for hepatotoxicity testing.3,4-Dihydroxy-benzohydroxamic acid (Didox) suppresses pro-inflammatory profiles and oxidative stress in TLR4-activated RAW264.7 murine macrophages.Microengineered cell and tissue systems for drug screening and toxicology applications: Evolution of in-vitro liver technologies.Subtoxic Concentrations of Hepatotoxic Drugs Lead to Kupffer Cell Activation in a Human In Vitro Liver Model: An Approach to Study DILI.Organotypic liver culture models: meeting current challenges in toxicity testing.In vitro models for liver toxicity testing.Metabolomic Study on Idiosyncratic Liver Injury Induced by Different Extracts of Polygonum multiflorum in Rats Integrated with Pattern Recognition and Enriched Pathways Analysis Idiosyncratic Drug-Induced Liver Injury (IDILI): Potential Mechanisms and Predictive Assays.An Update on Drug-induced Liver Injury.Trovafloxacin potentiation of lipopolysaccharide-induced tumor necrosis factor release from RAW 264.7 cells requires extracellular signal-regulated kinase and c-Jun N-Terminal Kinase.Animal models of idiosyncratic drug-induced liver injury--current status.Role of immune reactions in drug-induced liver injury (DILI).An evaluation of the latest in vitro tools for drug metabolism studies.Hepatotoxicity mechanisms of isoniazid: A mini-review.Hepatotoxicity of New Oral Anticoagulants (NOACs).Metabolic activation and drug-induced liver injury: in vitro approaches for the safety risk assessment of new drugs.Current limitations and future opportunities for prediction of DILI from in vitro.The Promise of New Technologies to Reduce, Refine, or Replace Animal Use while Reducing Risks of Drug Induced Liver Injury in Pharmaceutical Development.Oral exposure to immunostimulating drugs results in early changes in innate immune parameters in the spleen.Opportunities and challenges in the wider adoption of liver and interconnected microphysiological systems.Current challenges and controversies in drug-induced liver injury.Screening for main components associated with the idiosyncratic hepatotoxicity of a tonic herb, Polygonum multiflorum.Evaluation of a human in vitro hepatocyte-NPC co-culture model for the prediction of idiosyncratic drug-induced liver injury: A pilot study.Co-culture of Hepatocytes and Kupffer Cells as an In Vitro Model of Inflammation and Drug-Induced Hepatotoxicity.Understanding drug-cytokine synergistic toxicity.Nonalcoholic Fatty Liver Disease Is a Susceptibility Factor for Perchloroethylene-Induced Liver Effects in Mice.Idiosyncratic Drug-Induced Liver Injury Due to Ciprofloxacin: A Report of Two Cases and Review of the Literature

P2860

Q27690772-E889C20B-CB32-47B2-B6A5-26A99106FAD6 Q28468549-D5DD4008-0253-47BC-891B-A75D99F7147A Q28552429-F4BF2F6C-850E-461C-89EA-86EDFE3B56BF Q30990061-62F61D1C-9DA4-43A3-9D14-9E4695832583 Q33750834-DF645AED-4774-490E-90C0-DC20CD732843 Q33755165-6BDD0D77-5E95-4789-A48B-4D2E2ED01CF6 Q34645248-D199456D-3D0E-472C-BC7E-7693B3C92E4E Q35533521-90B1531D-89FA-4569-B098-00A4BEE5484A Q35826421-43ECBC9A-78B2-4C3A-AF87-F9C09CE1024D Q36146271-37071D0F-EB5C-4271-9586-1D4E47A5184E Q36178225-7C1AA580-C2C3-45D9-B7D5-03BF735E19D6 Q36671339-1C1408D3-6CC6-4186-9367-50A9134A92DB Q37504121-3A565DE4-0C3F-47C4-8568-283F858F6CEE Q37590883-6D5B0801-3271-42A7-847C-9CACE92788FB Q37613520-C16A35CB-AE6B-41DC-A11C-13738231891A Q37707739-ACAAE237-ADEB-4EE1-AC45-F8B68F216EE7 Q37897219-ACF27501-D31F-4407-95EB-EB960CF39881 Q37974923-8E63E9EB-B9E2-4E7B-B62A-ACAA8C3952C0 Q38160881-03450E66-3DFB-4038-9A8F-645FB29EE60A Q38533596-747DDCAC-DBA4-4545-8B84-98E79426E584 Q38542198-74C5DB64-070B-4063-82C5-D7FB705993D5 Q38675826-AD2ECD98-FF5F-4DBB-B78B-3A3AC192B031 Q38739197-3AD72C87-EFC3-4B5B-A8B7-2A1ADD09F900 Q38774776-0E962EFF-155E-46C1-91A7-40DC353EFEF3 Q38886199-A9912A4D-37E6-4FC5-B155-7521911625B6 Q39306694-E65501A5-47F0-4BE9-A953-7BD22EAD1C63 Q39523252-E3E70B11-B7B5-4E92-B6DB-557F43E46B08 Q40289628-E4F92A39-B5EF-4A00-AB81-006421CD055E Q41679143-0B4520B5-8AB5-4181-8459-36E034A08E5D Q41878584-ACC01330-1477-423D-B6CC-980E330820F3 Q43142253-6D2D44A6-92CB-4C65-BD90-D6A5D135C0CB Q47951000-42CD8AC5-650E-4810-8F04-41EDA4B79BDD Q58795536-EE05BD4B-80F2-481B-B6AF-06900F8976A3

P2860

Idiosyncratic drug-induced liver injury and the role of inflammatory stress with an emphasis on an animal model of trovafloxacin hepatotoxicity

http://www.wikidata.org/entity/Q34200596

description

2010 nî lūn-bûn

@nan

2010 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Idiosyncratic drug-induced liv ...... f trovafloxacin hepatotoxicity

@ast

Idiosyncratic drug-induced liv ...... f trovafloxacin hepatotoxicity

@en

Idiosyncratic drug-induced liv ...... f trovafloxacin hepatotoxicity

@nl

type

label

Idiosyncratic drug-induced liv ...... f trovafloxacin hepatotoxicity

@ast

Idiosyncratic drug-induced liv ...... f trovafloxacin hepatotoxicity

@en

Idiosyncratic drug-induced liv ...... f trovafloxacin hepatotoxicity

@nl

prefLabel

Idiosyncratic drug-induced liv ...... f trovafloxacin hepatotoxicity

@ast

Idiosyncratic drug-induced liv ...... f trovafloxacin hepatotoxicity

@en

Idiosyncratic drug-induced liv ...... f trovafloxacin hepatotoxicity

@nl

P1433

Q34200596-04750636-F805-409C-AF4F-6462C30925C2

P1476

Q34200596-4CA87357-054B-4474-9F1D-199E5FF2DB98

P2093

Q34200596-52B20C52-9CF9-4407-8C0B-20D4847504C1

Q34200596-949EACBC-3467-4F12-80BE-88B37095F1AA

Q34200596-BD4542BB-6868-43B1-8F7A-8731F5520EE3

P2860

Q34200596-0435DA00-D724-4F58-A424-1B1C93DD55DF

Q34200596-07A2EF63-A31C-4E0F-922A-381AD0BBE6A9

Q34200596-088DFBA6-973B-4BF1-8A9A-59D9C44119B4

Q34200596-099F85C3-B9FF-4094-B33E-E7809B00978F

Q34200596-0C8F2FA6-EC25-41D4-BE15-71596891A569

Q34200596-102249A5-A36F-478F-990D-5097F5925945

Q34200596-1211D914-5C7A-48E2-A30E-4D5847970CBD

Q34200596-12AB18CA-3123-4D8C-AE90-8135AF7194B4

Q34200596-14A180D2-AF2B-4899-AE73-67D403DC0CA2

Q34200596-16C59CAD-E9CF-42E7-9865-706F1D4126D9

P304

Q34200596-380C59E3-1704-4AAF-86EC-DFD46AEB28EE

P31

Q34200596-D76A09A8-CB11-4506-AAEF-F877C85F229B

P356

Q34200596-E52D4F7E-9AB9-478E-AC5C-E0AD07F21D0E

P433

Q34200596-A53A2CE7-E023-48B9-A93F-480BF7CF8C9B

P478

Q34200596-BF06D780-C6C1-41D4-AF0C-BBBF78352008

P577

Q34200596-16AAD99D-70A4-4E6C-AE06-9EBFA5F1A20D

P5875

Q34200596-16B2DDA9-DC04-4275-89BB-27C727B421AA

P698

Q34200596-05F8EDCF-FBBC-4494-B614-BD608C2043C5

P921

Q34200596-6C5C82FB-E8F7-4DBA-89BA-7327D645B108

Q34200596-AAE2CC7C-BCB2-47D4-B4A4-BC7260095A90

P932

Q34200596-92D9FFE1-3957-4066-AAA2-5F731A606AE1

P356

P1433

Toxicological Sciences

P1476

Idiosyncratic drug-induced liv ...... f trovafloxacin hepatotoxicity

@en

P2093

Patricia E Ganey

http://www.w3.org/2001/XMLSchema#string

Patrick J Shaw

http://www.w3.org/2001/XMLSchema#string

Robert A Roth

http://www.w3.org/2001/XMLSchema#string

P2860

Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients

Adverse reactions to fluoroquinolones. an overview on mechanistic aspects

Timing of new black box warnings and withdrawals for prescription medications

Isoniazid-associated hepatitis in 114 patients

Trovafloxacin-induced acute hepatitis

Bromfenac (Duract)-associated hepatic failure requiring liver transplantation

Troglitazone-induced fulminant hepatic failure. Acute Liver Failure Study Group

Detection of autoantibodies directed against human hepatic endoplasmic reticulum in sera from patients with halothane-associated hepatitis

Mechanisms of trovafloxacin hepatotoxicity: studies of a model cyclopropylamine-containing system.

Drug discovery, drug development and the emerging world of pharmacogenomics: prospecting for information in a data-rich landscape.

P304

7-18

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/TOXSCI/KFQ168

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

118

http://www.w3.org/2001/XMLSchema#string

P577

2010-06-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

44664222

http://www.w3.org/2001/XMLSchema#string

P698

20538741

http://www.w3.org/2001/XMLSchema#string

P921

P932

2955207

http://www.w3.org/2001/XMLSchema#string